Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mistelbach – page 14

889 clinical trials in Mistelbach, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mistelbach at a glance
889
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

889 trials in Mistelbach

Open in trial search

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:DB-1303
  • Sponsor:BioNTech SE

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Comparing brincidofovir and cidofovir for treating adenovirus infection in children and adults after stem cell transplantation

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Cidofovir
  • Sponsor:Symbio Pharmaceuticals Ltd.

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Insel Gruppe AG

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Xelafaslatide
  • Sponsor:ONL Therapeutics Inc.

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:ECRI-trials B.V.

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mistelbach

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on stroke prevention and management of atrial fibrillation. Research evaluates innovative treatments comparing asundexian to established medications for reducing stroke risk in patients with irregular heartbeat.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Systemic Embolism Prevention

Trials aim to assess both effectiveness and safety profiles of new therapeutic approaches.

02 Oncology Studies

Advanced research in breast cancer treatment, specifically focusing on hormone receptor-positive/HER2-negative early breast cancer. Studies evaluate the effectiveness of combining palbociclib with standard endocrine therapy.

  • Early Breast Cancer Treatment
  • Endocrine Therapy Enhancement
  • Disease-Free Survival Assessment

Research aims to improve treatment outcomes through innovative combination therapies.

03 Neurology Research

Innovative studies examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Research evaluates the efficacy of milvexian in reducing stroke risk compared to placebo.

  • Acute Stroke Treatment
  • Ischemic Attack Prevention
  • Neurological Recovery

Focus on developing more effective interventions for stroke prevention and management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.